接受多靶点治疗的儿童狼疮性肾炎患者霉酚酸暴露-反应关系:一项观察性队列研究
该观察性队列研究纳入48例接受霉酚酸酯、他克莫司和泼尼松多靶点治疗的儿童狼疮性肾炎患者,采用有限采样策略计算霉酚酸0-12小时血药浓度-时间曲线下面积(MPA-AUC0-12h),通过ROC分析确定肾脏缓解和无活动性系统性红斑狼疮的MPA-AUC0-12h阈值,并发现达到阈值者肾脏应答或无活动性SLE更迅速。
要点
- 6个月肾脏缓解的MPA-AUC0-12h阈值为25.24 μg·h·mL⁻¹,AUC为0.83(P=0.0002)。
- 12个月肾脏缓解的MPA-AUC0-12h阈值降至23.52 μg·h·mL⁻¹,AUC为0.89(P<0.0001)。
- 6个月无活动性SLE的MPA-AUC0-12h阈值为31.16 μg·h·mL⁻¹,AUC为0.80(P=0.0004)。
核心结论
- 儿童狼疮性肾炎多靶点治疗中MPA-AUC0-12h与治疗反应显著相关,建议根据个体MPA-AUC0-12h水平调整霉酚酸酯剂量。
研究设计与样本
- 观察性队列研究纳入48例接受霉酚酸酯、他克莫司和泼尼松多靶点治疗的儿童狼疮性肾炎患者,采用有限采样策略计算MPA-AUC0-12h。
主要发现
- 6个月肾脏缓解的MPA-AUC0-12h阈值为25.24 μg·h·mL⁻¹,ROC曲线下面积(AUC)为0.83(P=0.0002)。
- 12个月肾脏缓解的MPA-AUC0-12h阈值降至23.52 μg·h·mL⁻¹,AUC为0.89(P<0.0001)。
- 6个月无活动性SLE的MPA-AUC0-12h阈值为31.16 μg·h·mL⁻¹,AUC为0.80(P=0.0004)。
- 12个月无活动性SLE的MPA-AUC0-12h阈值降至28.87 μg·h·mL⁻¹,AUC为0.82(P=0.0012)。
- 达到MPA-AUC0-12h目标阈值的患者更迅速地获得肾脏应答或无活动性SLE。
关键数值与推荐
- 6个月肾脏缓解的MPA-AUC0-12h阈值为25.24 μg·h·mL⁻¹(AUC 0.83,P=0.0002)。
- 12个月肾脏缓解的MPA-AUC0-12h阈值为23.52 μg·h·mL⁻¹(AUC 0.89,P<0.0001)。
- 6个月无活动性SLE的MPA-AUC0-12h阈值为31.16 μg·h·mL⁻¹(AUC 0.80,P=0.0004)。
- 12个月无活动性SLE的MPA-AUC0-12h阈值为28.87 μg·h·mL⁻¹(AUC 0.82,P=0.0012)。
临床怎么用
- 作者建议根据个体MPA-AUC0-12h水平调整霉酚酸酯剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish the effectiveness threshold of mycophenolic acid-area under the concentration-time curve between 0 h and 12 h (MPA-AUC0-12h) in pediatric lupus nephritis (LN) patients receiving multi-target therapy. METHODS: This observational cohort study enrolled 48 pediatric LN patients treated with mycophenolate mofetil (MMF), tacrolimus, and prednisone. MPA-AUC0-12h was calculated using concentrations based on a limited sampling strategy. Binary logistic regression analysis was employed to investigate factors influencing efficacy. Receiver operating characteristic analysis was conducted to assess MPA-AUC0-12h threshold values. The cumulative incidence of renal remission and inactive systemic lupus erythematosus (SLE) over time was evaluated using Kaplan-Meier analysis. The t-test or Mann-Whitney test was utilized for comparisons between two groups of continuous variables. RESULTS: To achieve renal remission, the MPA-AUC0-12h threshold at 6 months was determined to be 25.24 μg·h·mL⁻¹, with an area under the ROC curve (AUC) of 0.83 (P = 0.0002). At 12 months, the MPA-AUC threshold decreased to 23.52 μg·h·mL⁻¹, yielding an AUC of 0.89 (P < 0.0001). For inactive SLE, the MPA-AUC0-12h threshold at 6 months was found to be 31.16 μg·h·mL⁻¹, with an AUC of 0.80 (P = 0.0004), while at 12 months it decreased slightly to 28.87 μg·h·mL⁻¹, resulting in an AUC of 0.82 (P = 0.0012). Patients who reached target thresholds for MPA-AUC0-12h achieved renal response or inactive SLE more rapidly. CONCLUSION: There is a significant correlation between MPA-AUC0-12h and treatment response in pediatric LN patients receiving multi-target therapy; therefore, it is recommended that MMF dosing be adjusted according to individual MPA-AUC0-12h levels.
引用
- Chen L, Zhang L, Liu B, et al. Exposure-response relationship of mycophenolic acid in pediatric lupus nephritis patients receiving multi-target therapy: An observational cohort study. Semin Arthritis Rheum. 2025. PMID: 40024071. doi:10.1016/j.semarthrit.2025.152674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。